Suzanne Nguyen

发表

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

A. Ginzac, M. Mouret-Reynier, X. Durando, 2024, Breast cancer research and treatment.